Tools
Stock profile

Cadre Holdings, Inc. (CDRE)

CDRE · Latest close $31.88 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$31.88
As of Nov 18, 2026
Tracked funds holding
1 of 149
2026 Q2 13F filings
Opened / added
1 / 0
vs previous quarter
Trimmed / exited
0
vs previous quarter

Cadre Holdings, Inc. (CDRE) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund opening new positions versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $6.5M sold). 1 member of Congress reported 1 purchase vs 0 sales. Latest close $31.88 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Aug 25, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-6.5M
Congress
1 buy vs 0 sales
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

First Eagle Investment Management — 1 tracked fund hold CDRE. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 4 sales ($6.5M). Insider trading 1 member of Congress reported buying (1 purchase vs 0 sales). Latest buy: Jun 30, 2026. Politician trading

Often held alongside

INTUITIVE SURGICAL INC (ISRG) · ZIMMER BIOMET HOLDINGS, INC. (ZBH) · Edwards Lifesciences Corp (EW) · ESTABLISHMENT LABS HOLDINGS INC. (ESTA) · MSA Safety Inc (MSA) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
First Eagle Investment Management0.01%306,458NEW Q3 filed Nov 10

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +13.3% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

46.0723.692024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding155 of 8,857 filers
Long-only filers among them155
Change vs 2026 Q1-7 net · 151 entered · 158 exited
Shares reported, all filers32,964,184
Reported value, all filers$895.1M

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNYSE
IndustryOrthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842)
Revenue · FY2025$610.3M
Net income · FY2025$44.1M
Total assets · FY2025$770.0M
Shares outstanding42,820,734
Market cap (at latest close)$1.4B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 31, 2026.

Short interest

Shares short · Oct 15, 20261,886,616
Share of shares outstanding4.41%
Days to cover3.21

Shares short at recent settlements — Jul 31, 2026: 3.1M · Aug 14, 2026: 2.3M · Aug 31, 2026: 2.2M · Sep 15, 2026: 2.3M · Sep 30, 2026: 2.0M · Oct 15, 2026: 1.9M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 31, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 24 · Aug 14, 2026: 0 · Aug 31, 2026: 3K · Sep 15, 2026: 0 · Sep 30, 2026: 2K · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 31, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 4 sales by 1 insider ($6.5M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Aug 25, 2026KANDERS WARREN BCEO AND CHAIRMANSell55,345$31.54$1.7MSEC filing
Aug 25, 2026KANDERS WARREN BCEO AND CHAIRMANSell44,655$32.28$1.4MSEC filing
Aug 24, 2026KANDERS WARREN BCEO AND CHAIRMANSell65,431$33.20$2.2MSEC filing
Aug 24, 2026KANDERS WARREN BCEO AND CHAIRMANSell34,569$33.65$1.2MSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Aug 25, 2026Warren B. KandersOfficer, Director100,000$3.2MAug 25, 2026SEC filing
Aug 24, 2026Warren B. KandersOfficer, Director100,000$3.3MAug 24, 2026SEC filing
Aug 17, 2026Brad WilliamsOfficer88,742$3.0MAug 17, 2026SEC filing
Jun 15, 2026Warren B. KandersOfficer, Director300,000$9.3MJun 15, 2026SEC filing
Mar 20, 2026Warren B KandersOfficer, Director200,000$6.3MMar 20, 2026SEC filing
Dec 12, 2025Blaine BrowersOfficer20,435$899.1KDec 12, 2025SEC filing
Dec 10, 2025Brad WilliamsOfficer24,000$1.0MDec 10, 2025SEC filing
Nov 17, 2025Warren B. KandersOfficer, Director1,343,941$56.6MNov 17, 2025SEC filing
Nov 13, 2025Brad WilliamsOfficer27,370$1.2MNov 13, 2025SEC filing
Oct 24, 2025Williams BradOfficer4,132$177.7KOct 24, 2025SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

Activist disclosure · Schedule 13D

FiledFormPrice change since disclosure
Sep 30, 2026SCHEDULE 13D/A+29.6% (close Oct 1, 2026 → Nov 17, 2026)

Reference close is the first trading day after the filing (Oct 1, 2026). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Sep 30, 2026Warren B. KandersSC 13D/A11,117,92825.8%Sep 28, 2026SEC filing
Aug 6, 2026FMR LLCSC 13G/A2,475,622.545.8%Jun 30, 2026SEC filing
Jun 18, 2026Warren B. KandersSC 13D/A11,392,92826.4%Jun 16, 2026SEC filing
May 14, 2026Capital International InvestorsSC 13G/A1,260,8063.0%Mar 31, 2026SEC filing
May 6, 2026FMR LLCSC 13G/A3,319,196.117.8%Mar 31, 2026SEC filing
Feb 12, 2026REINHART PARTNERS, LLC.SC 13G2,170,3495.3%Dec 31, 2025SEC filing
Feb 5, 2026FMR LLCSC 13G/A3,798,654.839.3%Dec 31, 2025SEC filing
Nov 19, 2025Warren B. KandersSC 13D/A11,692,57027.7%Nov 17, 2025SEC filing
Nov 14, 2025Warren B. KandersSC 13D13,036,51130.9%Nov 10, 2025SEC filing
Aug 12, 2025Warren B. KandersSC 13G/A11,823,51128.9%Jun 30, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

1 member of Congress reported buying (1 purchase vs 0 sales). Bought by Democrats. Latest buy: Jun 30, 2026.

Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.

Recent activity by member

MemberChamberPartyBuysSellsLatestAmount range
Cisneros, GilbertHouseD10Jun 30, 2026$1,001 - $15,000

Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.

Committee jurisdiction

Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: no Lobbying Disclosure Act filings matched for this ticker (1999–2026).

Federal contracts: $3.0M in obligated amounts, fiscal years 2021–2026.

Fiscal yearObligated amount
FY2021$2.2M
FY2022$543.0K
FY2023$0
FY2024$45.8K
FY2025$0
FY2026$169.7K

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Politicians

· Bought by Members — Last 6 months: bought by a member of the U.S. Congress

Financial Screens

· Growth — Revenue up every year for 5 straight years

· Graham — Sound finances and a long run of profits

· Earnings Quality (Cash Conversion) — Profits that actually come back as cash

Key figures

· Growth — Latest revenue: $610.3M · 5-yr revenue CAGR: 8.6% · Straight growth years: 5

· Graham — Current ratio: 3.50 · Straight profitable years: 6 · Debt ratio: 1.42 · Latest net income: $44.1M

· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.41 · Operating cash flow: $63.7M · Net income: $44.1M

· Bought by Members — Members buying: 1 · Buy txns: 1 · Sell txns: 0 · Latest buy: Jun 30, 2026

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Also held by the tracked funds that hold CDRE — ranked by lift, the co-holding pattern described in Methodology: INTUITIVE SURGICAL INC (ISRG) · ZIMMER BIOMET HOLDINGS, INC. (ZBH) · Edwards Lifesciences Corp (EW) · ESTABLISHMENT LABS HOLDINGS INC. (ESTA) · MSA Safety Inc (MSA) · STERIS plc (STE) · ALIGN TECHNOLOGY INC (ALGN) · Enovis CORP (ENOV).

8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

FiledItemsSource
Nov 16, 20265.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain OfficersSEC filing
Nov 4, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Aug 7, 2026 · 8-K/A2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

INTUITIVE SURGICAL INC (ISRG) · Track Record: how the signals scored · Practice timing on CDRE

One email a week: the week’s new filings and research. Subscribe free

← CDP  ·  CDW →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.